Fast Data Science are pleased to announce that the Clinical Trial Risk Tool, has been accepted as a supplier on the UK Government’s G-Cloud 15 framework.
The G-Cloud 15 framework allows public sector bodies to buy cloud-based computing services such as AI, hosting, software and support directly without lengthy, costly traditional tender processes.
The Clinical Trial Risk Tool helps users to analyse clinical trial protocols and documents. By identifying potential design risks early in the trial planning stage, the tool helps investigator, CROs, and sponsors.
More information is available here.
You can also check out our white paper.
The addition of the Clinical Trial Risk Tool to G-Cloud 15 streamlines access for UK public sector organisations in several key ways:
Pre-vetted procurement: Fast Data Science has undergone standard government assessments, ensuring transparent pricing, robust security, and compliant terms of service.
Fast contracting: Public sector buyers can bypass complex procurement cycles and acquire licenses directly via the Digital Marketplace.
To learn more about the Clinical Trial Risk Tool or to request a demo for your organisation, visit https://clinicaltrialrisk.org.
Fast Data Science is a UK-based data science consultancy specialising in artificial intelligence, machine learning, and natural language processing solutions for healthcare, pharmaceuticals, and public sector organisations.
Estimating the total cost of a clinical trial before it runs is challenging. Public data on past trial costs can be hard to come by, as many companies guard this information carefully. Trials in high income countries and low and middle income countries have very different costs. Upload your clinical trial protocol and create a cost benchmark with AI Protocol to cost benchmark The Clinical Trial Risk Tool uses AI and Natural Language Processing (NLP) to estimate the cost of a trial using the information contained in the clinical trial protocol.
You can download a white paper about clinical trial cost benchmarking here Estimating the total cost of a clinical trial before it runs is challenging. Public data on past trial costs can be hard to come by, as many companies guard this information carefully. Trials in high income countries and low and middle income countries have very different costs. Clinical trial costs are not normally distributed.[1] I took a dataset of just over 10,000 US-funded trials.
Guest post by Safeer Khan, Lecturer at Department of Pharmaceutical Sciences, Government College University, Lahore, Pakistan Introduction The success of clinical studies relies heavily on proper financial planning and budgeting. These processes directly impact key factors such as project timelines, resource allocation, and compliance with regulatory requirements. The accurate forecasting of costs for clinical trials, however, is a highly complex and resource-intensive process. A study by the Tufts Center for the Study of Drug Development found that the average cost of developing a new drug is approximately $2.
